727 reports of this reaction
3.2% of all RIFAMPIN reports
#4 most reported adverse reaction
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS is the #4 most commonly reported adverse reaction for RIFAMPIN, manufactured by Sanofi-Aventis U.S. LLC. There are 727 FDA adverse event reports linking RIFAMPIN to DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS. This represents approximately 3.2% of all 22,393 adverse event reports for this drug.
Patients taking RIFAMPIN who experience drug reaction with eosinophilia and systemic symptoms should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS is moderately reported among RIFAMPIN users, representing a notable but not dominant share of adverse events.
In addition to drug reaction with eosinophilia and systemic symptoms, the following adverse reactions have been reported for RIFAMPIN:
The following drugs have also been linked to drug reaction with eosinophilia and systemic symptoms in FDA adverse event reports:
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS has been reported as an adverse event in 727 FDA reports for RIFAMPIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS accounts for approximately 3.2% of all adverse event reports for RIFAMPIN, making it a notable side effect.
If you experience drug reaction with eosinophilia and systemic symptoms while taking RIFAMPIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.